Blanket prescribing of beta-blockers to all patients with CAD or at risk of CAD does not reduce cardiovascular risk

Beta-blocker therapy is not associated with a lower risk of death, nonfatal myocardial infarction (MI), and nonfatal stroke in patients with coronary artery disease (CAD) risk factors, known CAD without MI, or prior MI, according to a recent observational study.

Pragnesh Vachharajani, MD"...Trends are changing, and the evidence is compelling to use beta-blockers for the indications that are found to be beneficial in newer clinical studies.”
-Pragnesh Vachharajani, MBBS, family physician in Ahmedabad, India

These findings are especially significant for patients in India, since CAD mortalities present an average of 5 to 10 years earlier in Indian patients than in people from Western countries. CAD is the leading cause of morbidity and mortality worldwide, and Indians have the highest mortality due to CAD in the world (JAMA. 2007;297(3):286-294).

Beta-blocker therapy in India is prescribed primarily for post-MI patients and those at risk of coronary events, said Pragnesh Vachharajani, MBBS, a family physician in Ahmedabad, India, and a member of mdCurrent-India’s Editorial Advisory Board. “This study could definitely help us understand the role of beta-blockers in a better way," he said.

The recent longitudinal study included 44,708 patients in the Reduction of Atherothrombosis for Continued Health (REACH) registry. The patients...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiovascular, Pharmacology, Primary Care and tagged , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.